Galectin Therapeutics Inc. has published a transcript of its recent Regulation FD Presentation, during which senior management provided an extensive update on the company's progress and outlook. The event was attended by the company's President and CEO, as well as other key executives, staff, and consultants. During the call, management highlighted the company's significant achievements over the past year, including the near completion of analyses from the NAVIGATE trial and active discussions with potential partners regarding the advancement of belapectin for patients with late-stage liver disease. The CEO emphasized the company's improved position, stating, "I have never been as excited as I am today, nor have I had the luxury of sharing such an extensive amount of meaningful information." The team also addressed the decision to unblind the NAVIGATE trial at the end of 2024 following communications with the FDA, and discussed the importance of recently analyzed biomarker data to further support belapectin's clinical potential. Management also shared their gratitude for the combined efforts of employees, consultants, patients, investigators, and scientific collaborators, with the CEO noting, "The combined efforts of many people, some very apparent and some behind the scenes, are why we are in this enviable position." Looking ahead, Galectin Therapeutics plans to continue engaging with the scientific and investor communities through additional key opinion leader $(KOL)$ events, presentations at upcoming congresses, and peer-reviewed publications. The full transcript can be accessed through the link below.